A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE)
Phase of Trial: Phase II
Latest Information Update: 01 Jan 2008
At a glance
- Drugs Caldaret (Primary)
- Indications Myocardial infarction
- Focus Therapeutic Use
- Acronyms EVOLVE
- 01 Jan 2008 Results have been published; primary endpoint met.
- 25 Jan 2006 New trial record.